Back to Newsroom

Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research

NORWOOD, MA — (Marketwired) — 08/07/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that recently analyzed skin biopsy histology data from its Phase 2 study of anabasum for the treatment of diffuse cutaneous systemic sclerosis will be presented at the 15th International Workshop on Scleroderma Research. The four-day biennial research meeting, centered on translational medicine related to systemic sclerosis (SSc), is being held August 5-9, 2017 at the University of Pittsburgh in Pittsburgh, PA.